JAK Inhibitor Safety for Treating AD

In this episode, Christopher Bunick, MD, PhD, associate professor of dermatology at the Yale School Medicine, and a Dermatology Times Editorial Advisory Board member, discusses a paper he recently co-authored, titled “JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies,” with Stefano Daniele, PhD candidate of the Medical Scientist Training Program at the Yale School of Medicine.